» Articles » PMID: 22787043

Contribution of Decreased Serotonin Release to the Antidyskinetic Effects of Deep Brain Stimulation in a Rodent Model of Tardive Dyskinesia: Comparison of the Subthalamic and Entopeduncular Nuclei

Overview
Journal J Neurosci
Specialty Neurology
Date 2012 Jul 13
PMID 22787043
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Mechanisms whereby deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal globus pallidus (GPi) reduces dyskinesias remain largely unknown. Using vacuous chewing movements (VCMs) induced by chronic haloperidol as a model of tardive dyskinesia (TD) in rats, we confirmed the antidyskinetic effects of DBS applied to the STN or entopeduncular nucleus (EPN, the rodent homolog of the GPi). We conducted a series of experiments to investigate the role of serotonin (5-HT) in these effects. We found that neurotoxic lesions of the dorsal raphe nuclei (DRN) significantly decreased HAL-induced VCMs. Acute 8-OH-DPAT administration, under conditions known to suppress raphe neuronal firing, also reduced VCMs. Immediate early gene mapping using zif268 in situ hybridization revealed that STN-DBS inhibited activity of DRN and MRN neurons. Microdialysis experiments indicated that STN-DBS decreased 5-HT release in the dorsolateral caudate-putamen, an area implicated in the etiology of HAL-induced VCMs. DBS applied to the EPN also suppressed VCMs but did not alter 5-HT release or raphe neuron activation. While these findings suggested a role for decreased 5-HT release in the mechanisms of STN DBS, further microdialysis experiments showed that when the 5-HT lowering effects of STN DBS were prevented by pretreatment with fluoxetine or fenfluramine, the ability of DBS to suppress VCMs remained unaltered. These results suggest that EPN- and STN-DBS have different effects on the 5-HT system. While decreasing 5-HT function is sufficient to suppress HAL-induced VCMs, 5-HT decrease is not necessary for the beneficial motor effects of DBS in this model.

Citing Articles

Study on Recovery Strategy of Hearing Loss & SGN Regeneration Under Physical Regulation.

Li Z, Gao Y, Chen X, Xu L, Li Z, Chai R Adv Sci (Weinh). 2024; 12(5):e2410919.

PMID: 39716878 PMC: 11791950. DOI: 10.1002/advs.202410919.


Systematic review of rodent studies of deep brain stimulation for the treatment of neurological, developmental and neuropsychiatric disorders.

Zhang K, Matin R, Gorodetsky C, Ibrahim G, Venetucci Gouveia F Transl Psychiatry. 2024; 14(1):186.

PMID: 38605027 PMC: 11009311. DOI: 10.1038/s41398-023-02727-5.


Deep Brain Stimulation in the Treatment of Tardive Dyskinesia.

Szczakowska A, Gabryelska A, Gawlik-Kotelnicka O, Strzelecki D J Clin Med. 2023; 12(5).

PMID: 36902655 PMC: 10003252. DOI: 10.3390/jcm12051868.


Pulsed Electrical Stimulation Enhances Consistency of Directional Migration of Adipose-Derived Stem Cells.

Lee M, Park Y, Hong S, Koo M, Cho M, Park J Cells. 2021; 10(11).

PMID: 34831069 PMC: 8616144. DOI: 10.3390/cells10112846.


Cellular, molecular, and clinical mechanisms of action of deep brain stimulation-a systematic review on established indications and outlook on future developments.

Jakobs M, Fomenko A, Lozano A, Kiening K EMBO Mol Med. 2019; 11(4).

PMID: 30862663 PMC: 6460356. DOI: 10.15252/emmm.201809575.


References
1.
Sandler N . Tardive dyskinesia associated with fluoxetine. J Clin Psychiatry. 1996; 57(2):91. View

2.
Ketai R . Interaction between fluoxetine and neuroleptics. Am J Psychiatry. 1993; 150(5):836-7. DOI: 10.1176/ajp.150.5.836b. View

3.
Lee K, Blaha C, Harris B, Cooper S, Hitti F, Leiter J . Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. Eur J Neurosci. 2006; 23(4):1005-14. DOI: 10.1111/j.1460-9568.2006.04638.x. View

4.
Lyons M . Deep brain stimulation: current and future clinical applications. Mayo Clin Proc. 2011; 86(7):662-72. PMC: 3127561. DOI: 10.4065/mcp.2011.0045. View

5.
Di Giovanni G, Esposito E, Di Matteo V . Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther. 2010; 16(3):179-94. PMC: 6493878. DOI: 10.1111/j.1755-5949.2010.00135.x. View